hVIVO
hVIVO is a specialist contract research organisation providing human challenge trial services for infectious and respiratory disease.
The company conducts controlled human infection studies across more than 14 validated viral challenge models, supporting the development of vaccines and antivirals for clients including seven of the top ten global biopharma companies.
Services are delivered from a purpose-built quarantine facility in Canary Wharf and include virology and immunology laboratory services under the hLAB brand.
Latest News
hVIVO Appoints Angela Hildreth as Chief Financial Officer
hVIVO has appointed Angela Hildreth as Chief Financial Officer and board director, effective 18 November, joining from Futura Medical after seven years as UK finance director at Shield Therapeutics. Interim CFO Richard Cotton will return to his role as a non-executive director.
hVIVO Acquires CRS Berlin, Expanding into Dermatology and Women's Health
hVIVO has acquired CRS Clinical Research Services Berlin GmbH, a Phase I/II clinical research unit with a contracted orderbook of approximately €10 million and a track record of 350 completed studies. The deal extends hVIVO's German network alongside its existing Mannheim and Kiel units, adding dermatology and women's health to its therapeutic range, and is expected to be immediately earnings accretive in FY26 under a nominal-upfront, earnout-based structure.